HJHasan Jilaihawi

Hasan Jilaihawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Jilaihawi has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Impact of Multiple‐Clip Implantation for Residual Mitral Regurgitation After Transcatheter Edge‐to‐Edge Repair

    by Takashi Nagasaka, Vivek Patel, Kazuki Suruga, Hidemasa Shitan, Yuchao Guo, Ofir Koren, Alon Shechter, Dhairya Patel, Tarun Chakravarty, Aakriti Gupta, et al.

    Background: Residual moderate or greater mitral regurgitation (MR) after transcatheter edge‐to‐edge repair is strongly associated with adverse clinical outcomes. However, the prognostic impact of implanting additional clips in patients with significant residual MR after the first clip remains uncertain. We evaluated the clinical and echocardiographic outcomes of multiple‐clip implantation for significant residual MR following placement of the initial clip. Methods: We retrospectively evaluated 826 patients with moderate or greater residual MR on intraprocedural transesophageal echocardiography after placement of the first clip during transcatheter edge‐to‐edge repair at the Cedars‐Sinai Medical Center from 2014 to 2023. Patients were categorized into single‐clip (n=113) and multiple‐clip (n=713) groups. The primary end point was the composite of all‐cause mortality and heart failure hospitalization at 1 year. Results: Procedural technical success and complication rates were comparable between groups. The multiple‐clip group demonstrated greater MR reduction and higher transmitral pressure gradients at discharge, 30 days, and 1 year. At 1 year, the composite end point occurred less frequently in the multiple‐clip group than in the single‐clip group (16.8% versus 29.2%; P =0.002), along with greater and more sustained improvement in New York Heart Association functional class. In subgroup analyses, multiple‐clip implantation consistently reduced major adverse cardiovascular events in patients with moderate as well as moderate–severe/severe residual MR. Conclusions: In patients with significant residual MR after implanting the first clip, multiple‐clip implantation improved MR reduction and 1‐year outcomes without increasing complications. Even in moderate residual MR, additional clips were associated with more favorable clinical outcomes.

  • Open Access

    Mitral Valve Lithotripsy With SmartCrack Balloon for Severe Calcified Mitral Stenosis: First‐in‐Human Experience

    by Kent Chak‐Yu So, Kevin Ka‐Ho Kam, Ling Na Geri Wong, Wang Hei Anselm Hui, Ching‐Wei Lee, Tawai Ngernsritrakul, Leo Kar Lok Lai, Simon Chow, Shing Fung Chui, Michael Lee, et al.

    Background: Mitral stenosis due to mitral annular calcification and calcific rheumatic heart disease (CRHD) remains challenging to treat. This first‐in‐human study evaluated the safety and feasibility of the dedicated SmartCrack lithotripsy balloon in patients with severe mitral stenosis secondary to mitral annular calcification or calcific rheumatic heart disease. Methods: High surgical risk patients underwent mitral lithotripsy with the SmartCrack system. Intraoperative measures included mitral valve area, transmitral pressure gradient, and mitral regurgitation severity, assessed pre‐ and post procedure. Follow‐up computed tomography evaluated calcification changes. The primary safety end point was adverse events within 7 days (death, stroke, or procedural complications). The primary efficacy end point was mitral valve area >1.5 cm 2 , ≥50% reduction in transmitral pressure gradient, or transmitral pressure gradient 2 ( P P <0.01). Follow‐up computed tomography revealed calcium cracks in 4 of 5 patients with mitral annular calcification, whereas no cracks were observed in patients with calcific rheumatic heart disease. At 30 days, most patients (n=8/10) reporting symptom improvement. Conclusions: This study demonstrates the procedural feasibility of the SmartCrack lithotripsy balloon when combined with balloon mitral valvuloplasty, potentially modifying valvular calcification and improving mitral valve area. Larger studies are needed to confirm its safety, effectiveness, long‐term durability, and clinical benefits.

  • Hemodynamic Flow Signatures: A Novel Paradigm for the Evaluation of Transcatheter Aortic Valve Performance

    by Annette Maznyczka, Ole De Backer, Vinayak N. Bapat, Charanjit S. Rihal, Amar Krishnaswamy, Hasan Jilaihawi, Imran Rashid, Alexander M.K. Rothman, Arif A. Khokhar, Niels Vejlstrup, et al.

    A new paradigm for understanding transcatheter aortic valve (TAV) success is emerging, which hinges on whether a device reinstates physiological aortic flow. Limitations of echocardiography prevent complex flow assessment. Meanwhile, 4-dimensional flow cardiac magnetic resonance offers superior quantification of time-resolved 3-dimensional flow dynamics, permitting assessment of systolic flow displacement (reflecting eccentricity), systolic flow reversal ratio (reflecting conduit inefficiency), wall shear stress, and energetic efficiency. Abnormal aortic flow can persist after TAV replacement, despite reduction in transvalvular gradient. Persistent nonphysiological flow is thought to increase energy losses, reduce left ventricular ejection efficiency, and impair optimal afterload reduction, which theoretically may limit left ventricular reverse remodeling. Restoration of near-normal flow is a plausible therapeutic target for evaluating TAV performance. However, whether physiological flow restoration post-TAV replacement may enhance left ventricular mass reduction, increase TAV durability, and improve patient-relevant outcomes is unknown, and further research is crucial. Future clinical translation of cardiac magnetic resonance flow metrics also depends on automated extraction of systolic flow displacement and systolic flow reversal ratio, and postprocessing standardization. This review provides a perspective on 4-dimensional flow cardiac magnetic resonance for evaluating aortic flow post-TAV replacement, which may have the potential to refine TAV platform selection, inform next-generation device design, and hypothetically predict left ventricular recovery.

  • Open Access

    Mitral Transcatheter Edge‐to‐Edge Repair in Younger Adults

    by Yuchao Guo, Vivek Patel, Jair Basantes de la Calle, Takashi Nagasaka, Kazuki Suruga, Hidemasa Shitan, Dhairya Patel, Tarun Chakravarty, Mamoo Nakamura, Aakriti Gupta, et al.

    Background: Younger patients aged ≤65 years who have significant comorbidities deemed unsuitable for surgery, transcatheter edge‐to‐edge repair (TEER) may serve as an alternative, although the long‐term outcomes remain uncertain. This study aimed to compare clinical outcomes after TEER between younger patients (aged ≤65 years) and elderly patients (aged >65 years). Methods: A retrospective analysis was performed on 1364 consecutive patients with mitral regurgitation. The primary end point was 3‐year all‐cause mortality. Optimal device success was defined as achieving mild or less residual mitral regurgitation and less than 5 mm Hg transmitral mean gradient. Results: In the current cohort, 247 patients (18.1%) were younger than 65 years (median age: 58 years; interquartile ranges: 52–62), with 62.8% being men. Those younger patients had lower left ventricular ejection functions and were more likely to have secondary mitral regurgitation, congestive heart failure. Despite a higher‐risk clinical profile, composite of all‐cause mortality, heart failure hospitalization, or reintervention after TEER were comparable between younger and older patients. Younger patients demonstrated significantly lower 3‐year all‐cause mortality compared with older patients (18.5% versus 30.3%, P =0.007). Younger patients with device success had the lowest mortality compared with elderly patients with unsuccessful procedures (13.9% versus 34.3%, P =0.001). Among patients with unsuccessful procedures, TEER did not improve outcomes in younger patients compared with older patients. Propensity‐matched analysis confirmed that younger patients continued to demonstrate lower 3‐year all‐cause mortality (18.5% versus 34%, P =0.034). Conclusions: Younger mitral regurgitation patients undergoing TEER had more advanced congestive heart failure but lower 3‐year mortality than elderly patients. However, those without optimal device success showed no survival benefit over their older counterparts, underscoring the need for close follow‐up and consideration of timely reintervention.

  • Automated AI-Based Aortic Measurements From Attenuation Correction CT as an Adjunctive Cardiovascular Risk Biomarker: An International Multicenter Study

    by Anna M. Marcinkiewicz, Aakash Shanbhag, Panithaya Chareonthaitawee, Wenhao Zhang, Hasanian Al-Jilaihawi, Ryan Zaid, Sebastien Cadet, Giselle Ramirez, Mark Lemley, Jirong Yi, et al.

    BACKGROUND: Aortic enlargement is a powerful predictor of dissection and rupture, yet it is rarely evaluated during routine myocardial perfusion imaging, despite the widespread availability of computed tomography (CT) attenuation correction scans. The aim of this study was to determine whether fully automated, opportunistically derived, artificial intelligence-based aortic measurements from myocardial perfusion imaging CT attenuation correction scans are associated with adverse outcomes in a large multicenter cohort. METHODS: Computed tomography attenuation correction scans from patients undergoing positron emission tomography/CT and single-photon emission CT/CT myocardial perfusion imaging across 10 centers were included. A deep learning model automatically segmented the thoracic aorta, and a postprocessing algorithm extracted maximum ascending and descending diameters. The aortic size index (1) was calculated by indexing the diameter to body surface area. RESULTS: A total of 29 339 patients (56% male; median age, 66 years [interquartile range, 58–75 years]) were included. Over a median follow-up of 3.5 years (interquartile range, 1.9–5.0 years), 5083 (17.3%) patients died. Median ascending and descending aortic size index values were 1.8 cm/m 2 (interquartile range, 1.6–2.0) and 1.5 cm/m 2 (interquartile range, 1.4–1.6), respectively, with an increase with age and higher values in females. Elevated aortic size index thresholds (ascending >2.2 cm/m 2 ; descending >1.6 cm/m 2 ) were significantly associated with increased all-cause mortality (ascending: adjusted hazard ratio, 1.16 [95% CI, 1.07–1.26], P P <0.001). Notably, the prognostic value of an abnormal aortic size index persisted independent of age, sex, and perfusion abnormalities. CONCLUSIONS: Artificial intelligence can unlock previously unused information within routine myocardial perfusion imaging CT attenuation correction scans by rapidly and automatically quantifying aortic size at scale. Opportunistic aortic measurements derived from CT attenuation correction may serve as an adjunctive risk biomarker and could add prognostic value to standard myocardial perfusion imaging without additional imaging or radiation.

  • Transcatheter Aortic Valve Replacement for Severe Bicuspid Aortic Valve Stenosis

    by Jung-Min Ahn, Sant Kumar, Euihong Ko, Gossadi Mohammed, Kentaro Hayashida, Wei-Hsian Yin, Hasan Jilaihawi, Raj Makkar, Won-Keun Kim, Tullio Palmerini, et al.

    Surgical aortic valve (AV) replacement has been the standard treatment for patients with severe symptomatic degenerative AV stenosis (AS). In recent years, transcatheter AV replacement has emerged as an established alternative in selected patient populations, supported by robust evidence in tricuspid AS. However, there has been limited evaluation of transcatheter AV replacement in bicuspid AV AS. Recently, several observational studies have demonstrated the feasibility and safety of transcatheter AV replacement in bicuspid AV AS, and the use of newer-generation devices has shown encouraging outcomes. However, the incidence of procedural complications such as paravalvular regurgitation, permanent pacemaker implantation, and aortic root injury was more frequent in patients with bicuspid AV AS compared with tricuspid AS. We review the clinical evidence of transcatheter AV replacement for bicuspid AV AS and suggest the appropriate criteria for patient and device selection, implantation techniques, and further management.


  • Open Access

    Comparing Clinical Outcomes of Patients With a Small Versus Large Annulus After Newer‐Generation Balloon‐Expandable Transcatheter Aortic Valve Replacement

    by Kazuki Suruga, Vivek Patel, Takashi Nagasaka, Yuchao Guo, Hidemasa Shitan, Daniel Ng, Tea Cohen, Tukika Garg, Prashant Ahlawat, Ofir Koren, et al.

    Background: Limited data are available comparing clinical outcomes between patients with small and large annuli following transcatheter aortic valve replacement using balloon‐expandable valves. This study sought to investigate 5‐year clinical outcomes in patients with severe aortic stenosis with a small annulus compared with those with a large annulus following transcatheter aortic valve replacement with newer‐generation balloon‐expandable valves. Methods: A total of 3182 patients with aortic stenosis treated with balloon‐expandable valves were divided into small‐annulus (≤430 mm 2 ) and large‐annulus (>430 mm 2 ) groups. A 1:1 propensity‐matched analysis was performed to adjust baseline differences. The primary end point was all‐cause death at 5‐year follow‐up. Secondary end points included heart failure hospitalization, bioprosthetic valve failure, and aortic valve reintervention. Results: Among 533 matched pairs, compared with the large‐annulus group, the small‐annulus group had higher rates of aortic valve mean gradients ≥20 mm Hg (14.1% versus 2.9%; P P =0.019). At 5 years, there were no significant differences in all‐cause death (hazard ratio, 0.75 [95% CI, 0.52–1.09]; P =0.13). The incidence of heart failure rehospitalization, bioprosthetic valve failure, and aortic valve reintervention were similar between groups. Both groups achieved similar sustained improvements in New York Heart Association functional class and Kansas City Cardiomyopathy Questionnaire–Overall Summary scores. Conclusions: Despite higher transvalvular gradients and a greater rate of severe prosthesis–patient mismatch, 5‐year clinical outcomes in patients with a small annulus were comparable to those with a large annulus following transcatheter aortic valve replacement using newer‐generation balloon‐expandable valves.

  • Open Access

    Long‐Term Clinical Outcomes of Balloon‐Expandable Versus Self‐Expanding Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annulus

    by Shubhadarshini Pawar, Vivek Patel, Takashi Nagasaka, Prateek Madaan, Amir Ghaffari Jolfayi, Ofir Koren, Dhairya Patel, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, et al.

    Background: Self‐expanding valves (SEVs) have demonstrated superior hemodynamic performance and comparable clinical outcomes to balloon‐expandable valves (BEVs) at 1 year in patients with a small aortic annulus. However, long‐term data are limited. This study aimed to evaluate 5‐year echocardiographic and clinical outcomes of SEVs versus BEVs in patients with small aortic annulus underwent transcatheter aortic valve replacement. Methods: We analyzed RESOLVE registry patients who underwent transcatheter aortic valve replacement at Cedars‐Sinai between 2015 and 2020. Patients with a small aortic annulus (2 by computed tomography) were included and followed for up to 5 years. The primary outcome was a composite of all‐cause mortality, stroke, or heart failure hospitalization. Secondary outcomes included myocardial infarction, pacemaker implantation, aortic valve reintervention, and structural bioprosthetic valve dysfunction. Results: Among 1392 transcatheter aortic valve replacement recipients, 423 (78 SEVs, 345 BEVs) met the small annulus criteria. SEVs were associated with lower transvalvular gradients and larger indexed effective orifice area at discharge and 1 year ( P P P P <0.33). All‐cause mortality, stroke, heart failure hospitalization, structural bioprosthetic valve dysfunction, and reintervention rates were similar between groups. Conclusion: Although SEVs provide better hemodynamic performance in patients with severe aortic stenosis and small annuli, this advantage did not translate into improved survival or reduced cardiovascular events at 5 years.